Gene-expression tester XDx marks the spot with an $86M IPO bid
October 27, 2007 | David P. Hamilton
See our story on this Brisbane, Calif., genomic-diagnostic firm at VentureBeat Life Sciences.
Next Story: IPO roundup: Bioheart, Merrion Pharma in limbo; Reliant vs. Reliant road shows; upcoming offerings
Previous Story: Facebook deal still hasn't happened
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.












